The lawsuit (PDF) victim is Rose Orta who filed a claim in the U.S
doi: 10.1023/A:1018909210879
In the coming years, the global obesity drug market may continue shifting toward triple agonists, oral peptide drugs, long-acting therapies, and next-generation peptide engineering technologies
A liquid pharmaceutical composition consisting essentially of a) 3.2 mg/ml semaglutide, optionally b) no more than 0.1 %(w/w) phenol, c) above 6.4 mg/ml sodium chloride, d) buffer, e) at least 60% water, optionally f) histidine, optionally g) one or more agents for adjusting pH, such as HCI, NaOH, or acetate, and said composition optionally has a pH of 6-10 such as 7-8
That creates a clinical and commercial gap that reformulated beverages can fill
At the same time, she announced a partnership with the company Ro, which prescribes GLP-1 medications through telehealth